A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukemia (AML) by helping doctors identify if they might relapse up to three months ...

Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...

SLS009 significantly improved survival in r/r AML patients, with a median overall survival of 8.8 months, surpassing historical benchmarks. The therapy showed a 67% objective response rate in AML-MRC ...

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

Orca-T significantly improved cGVHD-free survival compared to allo-HSCT, with a 78% vs 38% rate at one year. The study reported a 94% overall survival rate for Orca-T, with no new safety concerns ...

Cytopenia in myelofibrosis patients increases the risk of AML progression and decreases overall survival, necessitating careful treatment selection. A retrospective cohort study found 70% of ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...